Portfoliotracker

Corbus Pharmaceuticals Holdings, Inc.

CRBP · NASDAQCM · Healthcare Biotechnology 15/100 E

3,375 $
▼ −0,015 (−0,44 %)
Pre-market delayed by 15 min
Price as of 16. 11. 22:00, fetched 17. 11. 13:41
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score15 / 100 Market cap65,5 mil. $ P/E– Forward P/E-0,6 P/S– P/B0,6 EV/EBITDA– Dividend yield– FCF yield– EPS-6,04 $ Net margin0,0 % Return on equity-131,5 % Beta2,79 Debt / equity0,05
52-week range 2,81 to 12,88
3-month average volume1,1 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.

Employees
36
Country
United States
Fiscal year end
31. 12.
Data since
27. 10. 2014

Explore further

Similar companies CRON

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account